IMPORTANCE Serious illness impairs function and threatens survival. Patients facing serious illness value shared decision making, yet few decision aids address the needs of this population.
ever, poor quality of communication between patients and practitioners limits the patients' knowledge of prognosis and treatment options, management of symptoms, and use of treatments consistent with their preferences. 4, 5 Structured tools are a novel method to improve knowledge transfer and promote patient engagement in health care choices. Tools that use print, video, or web-based media are designed to share information about an illness and promote informed decisions about treatment. These tools are not a substitute for clinical communication, but are intended to prepare and empower patients and their families for shared decision making with clinicians. Some tools are designed to improve the patients' knowledge about clinical issues. Other tools are formal decision aids, which are more highly structured to address the risks and benefits of and alternatives to treatment and are designed to prepare patients for their role in key decisions. 6 Randomized clinical trials (RCTs) have shown that decision aids improve the quality and efficiency of decision making, increase comprehension and decisional participation, and decrease decisional conflict. 7 Despite the importance of shared decision making in serious illness, most formal decision aids have addressed the needs of healthier outpatients, and a recent Cochrane review excluded advance care planning (ACP) tools. 8 No systematic review, to our knowledge, has synthesized the evidence for communication tools and decision aids in serious illness. We therefore sought to assess the quality and accessibility of decision aids and tools for ACP designed to empower and improve the care of patients with serious illness. To meet this objective, we conducted a systematic review of published clinical trials of decision aids and ACP tools to promote shared decision making in serious illness. The goals of this study are to (1) identify tools relevant to the needs of treatment decision making by seriously ill patients and their caregivers, (2) evaluate the quality of evidence for these tools, and (3) summarize their effect on patient-centered outcomes and accessibility of tools for clinicians.
Methods

Data Sources and Searches
We searched PubMed, CINAHL, and PsychInfo from January 1, 1995, through October 31, 2014, and identified additional studies from reference lists and relevant systematic reviews. Our electronic search strategy included the following terms using text word (tw) 
Study Selection
This systematic review includes published nonrandomized clinical trials and RCTs that test decision tools intended for use by patients and their caregivers. Studies were included if they tested tools to improve treatment decision making for patients living with serious illness. Decision tools were included whether or not they met the International Patient Decision Aid Standards Collaboration definition for decision aids, that is, tools that present treatment options in a balanced and evidence-based manner.
8 Tools were included if they were structured for use by the patient or family caregiver without immediate clinician support. For instance, we excluded interventions that required communication training for clinicians or extensive patient coaching. Formats included print, video, or webbased decision tools. Content had to be relevant for communication about major treatment decisions in serious illness. Included studies could be from any health care setting or country if they were written in English and amenable to quality analysis. Given the early stage of this field of research, we accepted randomized or nonrandomized controls and diverse outcomes and lengths of follow-up. We defined an eligible patient population as adults living with advanced-stage or potentially life-limiting diseases, including critical illness, metastatic cancer, advanced stages of renal or liver disease, chronic obstructive pulmonary disease, cystic fibrosis, systolic congestive heart failure, human immunodeficiency virus infection and/or AIDS, or advanced neurodegenerative diseases, such as Parkinson disease, amyotrophic lateral sclerosis, or dementia. Studies were excluded if they addressed prevention or stable chronic disease at an early stage. Because communication and decision making differ greatly for children, we included only interventions for patients 18 years or older.
Two of us (D.M. and L.C.H.) reviewed all titles and abstracts and excluded abstracts that did not address patients with serious illness. Two of us (C.A.A. and L.C.H.) independently reviewed all the remaining abstracts and excluded observational studies, studies of patients with insufficient illness severity, or studies of nonexportable interventions. At least 2 of us then examined each full article of the remaining published studies to determine final inclusion and exclusion. Any disagreements were resolved by consensus discussion. Additional studies were accepted after hand searching reference lists of the included studies and asking content experts for additional suggestions.
Data Extraction and Quality Assessment
We created a standardized data extraction instrument to prepare evidence tables. This instrument followed the CONSORT criteria 9,10 and the 
Data Synthesis and Analysis
Two of us (C.A.A. and L.C.H.) analyzed the studies' risk for bias based on the presence or absence of the following 8 elements: randomization with or without allocation concealed, blinding of outcome assessment, blinding of participants, specification of outcomes, specification of inclusion criteria, greater than 75% completion of outcome data, adjustment for confounding, and intention-to-treat analysis. Analysis followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria used in Cochrane systematic reviews. 12,13 Studies meeting 5 or more of these criteria were assessed as high quality (GRADE A) with a low risk for bias; those meeting 3 to 4 criteria, as intermediate quality (GRADE B) with a medium risk for bias; and those meeting 0 to 2 criteria, as lower quality (GRADE C) with a high risk for bias. To reduce bias in reporting, one of us (C.A.A.) led the review of studies authored by investigators conducting this systematic review. We used the PRISMA checklist to design and report the study.
14 To summarize the potential clinical impact of each decision tool, we developed categories to describe the degree of change in patientcentered outcomes. Interventions that lead to improvement in patient outcomes of symptom distress, satisfaction, or quality of life or changes in treatment experiences were termed high impact. Tools with evidence of patient or caregiver behavioral changes or actual treatment choices were termed moderate impact. Tools with no effect on outcomes or those addressing intermediate outcomes, such as change in knowledge or attitudes, were termed lesser impact. To describe the accessibility of each tool, we searched the published studies and the Internet for information on how to view and use the tool and whether it was free or had to be purchased.
Results
Of the initial 9995 titles identified by the search strategy, 389 met our criteria for full abstract review, and 110 met our criteria for full text review. Seventy-five studies were excluded, and 3 additional titles were included from hand searching reference lists. In total, 38 articles met all inclusion criteria (Figure) .
Seventeen of the included studies were RCTs, and the remaining 21 studies were trials with a small pilot or preinterventionpostintervention study design. Six of the RCTs tested tools for ACP for future decisions, and 11 tested tools to support immediate treatment choices.
Small Pilot and Preintervention-Postintervention Studies
The 21 pilot studies 7,15-34 were designed to examine feasibility and to provide preliminary evidence for newly developed decision tools ( Table 1 ). Three high-quality (GRADE A) clinical trials tested a 2-minute video developed by Volandes et al [35] [36] [37] on features of advanced dementia to inform ACP discussions, should individuals develop this health condition. Each study tested the video in different outpatient populations. The largest of these 3 trials 35 enrolled 200 outpatients 65 years and older and found that viewing the video resulted in a significant increase in patients reporting that they would choose comfort as their primary goal for a future health state of advanced dementia (86% vs 64%; P = .003). Another study 37 examined 76 rural outpatients and demonstrated an increased choice of comfort as their primary goal for advanced dementia (91% vs 72%; P < .001). A third study of 14 outpatients older than 65 years 36 demonstrated increased concordance between patients and their surrogates after viewing the video (100% vs 33%; P = .02). These trials examined immediate preference change, but they did not examine outcomes such as documentation of preferences or discussion of preferences with health care practitioners. The remaining 3 ACP studies 43-45 tested the effect of 3 different tools on the expression and documentation of treatment preferences. One high-quality (GRADE A) RCT by Sudore et al 43 examined an advance directive that was modified for patients with lower health literacy and found it improved ease of use when compared with a standard advance directive document (69.1% vs 48.7%; P < .001). Six months later, those patients who used the literacyadjusted advance directive were more likely to have completed a written directive (18.5% vs 7.7%; P = .03). The RCT by Pearlman et al 44 
was of intermediate quality (GRADE B). The authors examined
an ACP workbook and found a significant increase in the discussion of ACP with health care practitioners (64% vs 28%; P < .001) and in documentation of living wills (48% vs 23%; P < .001). Finally, a poor-quality small RCT 45 tested a website to promote ACP and palliative care consultation for women with ovarian cancer. This small study found no effect of the website tool on advance directive completion or palliative care consultation.
RCTs of Decision Tools for Current Treatment
Eleven RCTs 38-42,46-51 tested decision tools to support current treatment choices in serious illness. All but 1 study 49 improved knowledge ( 15-minute online module intended to help patients with metastatic cancer prepare for an initial oncology visit. Although no change in decisional conflict or choice of palliative chemotherapy was observed, the authors noted an increase in satisfaction with (P = .03) and ease of decision making (P < .01).
In a large high-quality (GRADE A) study by Yun et al, 51 a booklet assisting family members with the decision about disclosure of of a decision tool for patients with cystic fibrosis who were considering lung transplant and found that the tool increased knowledge and realistic expectations while decreasing decisional conflict (P < .001). However, the tool did not change the choice to undergo transplant at 12 months.
Discussion
Key Findings
This study is, to our knowledge, the first systematic review of clinical tools to improve communication and decision making for patients facing serious illness. Seventeen RCTs, nearly all of moderate or high quality, form the primary body of evidence for these tools. Study results show that decision tools clearly improve patient Only 2 tools are standardized decision aids-one addressing feeding options in dementia care 40 and one addressing advanced treatment choices in cystic fibrosis. 50 Decision aids differ in important ways from other decision tools and meet formal standards for framing the presentation of medical information to patients in line with principles of shared decision making.
6
This study makes a novel contribution to the existing literature by systematically reviewing exportable decision tools designed to empower patients and caregivers in decision making. However, these data have important limitations. Many study populations were small, leaving studies inadequately powered for meaningful results. Study populations all have serious illness, but diagnoses are heterogeneous and limit conclusions about application to specific diseases. More than half of the identified studies used convenience samples and followed a preintervention-postintervention study design. The nature of interventions designed to improve these outcomes often results in a nonblinded study design. We only searched for articles published since 1995, so we might have missed earlier articles. However, our review did not reveal any articles before 1998; therefore, this possibility seems less likely. Finally, this review is limited to published research. The analysis might have had a publication bias toward positive studies that could skew our review. However, some of the studies reviewed reported negative findings, so this possibility seems less likely.
Implications
Given the clear need to improve shared decision making in serious illness, improving this body of evidence should be a research priority. Research is needed to test decision aids for major serious illnesses, such as advanced heart failure or end-stage renal disease. Because the effect on knowledge is well established, future research needs to focus on outcomes measuring the effect of the change in knowledge on treatment decisions, receipt of care consistent with preferences, and satisfaction with care. Furthermore, decision aids for the seriously ill could reduce health care intensity and costs by decreasing unwanted major high-cost interventions or hospitalizations; these outcomes have not been studied.
Tools to promote patient engagement in treatment decisions are a policy priority in the United States since the passage of the Affordable Care Act.
53 Therefore, investigators with proven tools may consider the importance of implementation research and effective dissemination strategies to ensure that clinicians and patients can truly benefit. Making proven decision tools available online or embedding them in electronic health record systems would be appropriate first steps. However, meaningful adoption of this novel practice may require peer leadership, incentives, new time and space in clinical settings, training, and feedback. This body of evidence is promising, yet it lags far behind the rapid dissemination of tools-primarily for ACP-that are developed outside a clinical research framework. A recent review by the Agency for Healthcare Research and Quality 54 combed scientific and gray literature sources to describe a multitude of published ACP tools that are diverse in quality and rarely supported by evidence of effectiveness or patient benefit. Unlike our study, that review excluded decision aids for current health care choices, which may be most relevant once serious illness develops. Healthcare organizations may be more successful at improving shared decision making if they demand decision tools with evidence of effectiveness. This phenomenon suggests a significant opportunity for collaboration in implementation, blending the best of decision science with the broad public reach of innovations in web-based technology.
Conclusions
A small but promising body of research demonstrates the clinical potential to improve patient engagement with tools to enhance decision making in serious illness. A small number of these tools are supported by evidence of their impact and are available for clinical practice. Future research should expand the work to new decisions in serious illness and emphasize outcomes beyond knowledge, such as care consistent with preferences and satisfaction with care.
